

FINANCIAL STATEMENTS (Unaudited)
For the period from 01.07.2025 to 31.12.2025



THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur,
Dhaka-1207, Bangladesh.

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF FINANCIAL POSITION (Unaudited)
As at 31 December 2025

		Amount in Taka	
		31 December 2025	30 June 2025
ASSETS:			
Non-Current Assets:		5,905,671,438	4,701,323,681
Property, Plant and Equipment	04.A	2,615,357,691	2,655,519,636
Capital Work-In-Progress	05.A	3,220,029,873	1,932,358,746
Right-of-Use Assets	05.B	20,670,445	33,072,711
Advances, Deposits & Prepayments	10.A.1	8,911,000	33,715,070
Financial Assets	06.A	40,702,429	46,657,518
Current Assets :		3,091,429,502	2,845,250,397
Financial Assets	7.B	59,144,491	22,500,000
Inventories	08.A	1,883,708,381	1,808,087,123
Trade and Other Receivables	09.A	226,845,888	196,052,607
Advances, Deposits & Prepayments	10.A.1	586,486,178	503,707,520
Cash & Cash Equivalents	11.A	335,244,563	314,903,147
TOTAL ASSETS		8,997,100,940	7,546,574,078
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Equity attributable to the owners of the company:		4,199,497,399	3,926,901,664
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(20,903,911)	(15,544,331)
Retained Earnings	15.A	3,903,572,930	3,625,617,615
Non Controlling Interests	15.B	105,263,184	70,946,596
LIABILITIES:			
Non-Current Liabilities:		1,086,880,262	1,072,158,461
Long Term Finance	16.A	984,777,983	974,705,376
Employee Benefit Obligations	17.A	1,629,086	990,546
Deferred Tax Liabilities	19	100,473,193	96,462,538
Current Liabilities:		3,605,460,095	2,476,567,357
Short Term Finance	20.A	1,797,387,709	953,683,239
Current Portion of Long Term Finance	21	59,746,323	119,445,855
Lease Liabilities	17.B	9,820,926	23,798,698
Trade and Other Payable	22.A	1,028,636,994	842,289,127
Unclaimed Dividend	22.B	72,718,559	42,104,508
Provision for Corporate Tax	23.A	637,149,585	495,245,930
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		8,997,100,940	7,546,574,078
Net Assets Value (NAV) Per Share	31.A	134.41	125.69

Chief Financial Officer

Company Secretary

Director


Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)
For the Half-Year ended 31 December 2025

					Amount in Taka
	Notes	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)	For the Quarter (1 October 2025 to 31 December 2025)	For the Quarter (1 October 2024 to 31 December 2024)
REVENUE	24.A	7,465,169,752	5,930,046,291	3,748,496,603	3,174,104,435
Cost of goods sold	24.C	(4,413,910,280)	(3,534,028,829)	(2,237,438,694)	(1,899,115,951)
GROSS PROFIT		3,051,259,472	2,396,017,462	1,511,057,909	1,274,988,484
OPERATING EXPENSES		(2,363,438,517)	(1,930,906,619)	(1,169,518,229)	(987,014,145)
Administrative expenses	25.A	(135,374,187)	(134,115,019)	(65,477,293)	(74,982,945)
Selling and Distribution expenses	26.A	(2,228,064,330)	(1,796,791,600)	(1,104,040,936)	(912,031,201)
OPERATING PROFIT		687,820,955	465,110,843	341,539,680	287,974,339
Finance charges	34	(51,452,579)	(38,753,623)	(24,745,892)	(20,151,925)
Other income		18,311,423	11,728,648	8,863,211	3,333,220
Profit before WPPF and welfare fund		654,679,799	438,085,868	325,656,999	271,155,634
Workers' P.P. fund and welfare fund	27.A	(32,129,881)	(25,290,807)	(16,030,186)	(14,730,378)
PROFIT BEFORE TAX		622,549,918	412,795,062	309,626,813	256,425,256
Income tax expenses	28.A	(145,318,801)	(116,927,876)	(53,321,464)	(45,470,421)
PROFIT FOR THE PERIOD		477,231,117	295,867,185	256,305,349	210,954,835
PROFIT /(LOSS) ATTRIBUTABLE TO:					
Owners of the Company		477,914,529	295,407,951	256,688,000	210,773,082
Non-controlling interest		(683,412)	459,234	(984,172)	181,754
		477,231,117	295,867,185	255,703,828	210,954,836
Other Comprehensive Income:					
Change in fair value of Marketable Securities	29	(5,955,089)	(3,056,462)	(9,259,763)	(8,290,512)
Less: Deferred tax		595,509	305,646	925,976	829,051
Total other comprehensive income for the period, net of tax		(5,359,580)	(2,750,816)	(8,333,787)	(7,461,461)
Total Comprehensive Income for the period		471,871,537	293,116,370	247,971,562	203,493,374
Total Comprehensive income Attributable to:					
Owner of the Company		472,554,949	292,657,136	248,354,213	203,311,622
Non-controlling interest		(683,412)	459,234	(984,172)	181,754
		471,871,537	293,116,370	247,370,041	203,493,376
Earnings Per Share (EPS)	30.A	15.27	9.47	8.20	6.75
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2025


Amount in Taka


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,718	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2025			(6,933,611)	633,189,350	66,877	626,322,617
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Issued during the year					35,000,000	35,000,000
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,625,617,614	70,946,595	3,997,848,260
Statement of profit or loss and other Comprehensive Income for period ended 31 December, 2025			(5,359,580)	477,914,529	(683,412)	471,871,536
Dividend for the year 30 June, 2025 (Cash-64%)				(199,959,213)		(199,959,213)
Issued during the period					35,000,000	35,000,000
Balance as at 31 December 2025	312,436,270	4,392,110	(20,903,912)	3,903,572,930	105,263,183	4,304,760,583

STATEMENT OF CHANGES IN EQUITY (Unaudited)
For the Half-Year ended 31 December 2024

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Non Controlling Interest	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,706,202,754	35,051,367	3,055,816,151
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	670,522,122	828,351	665,006,105
Dividend for the year 30 June 2023 (Cash-60%)				(187,461,762)		(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,189,263,114	35,879,719	3,533,360,493
Statement of profit or loss and other Comprehensive Income for period ended 31 December, 2024			(2,750,816)	295,407,951	459,234	293,116,369
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)		(196,834,850)
Balance as at 31 December 2024	312,436,270	4,392,110	(11,361,537)	3,287,836,215	36,338,953	3,629,642,013


Chief Financial Officer


Company Secretary


Director


Dated, Dhaka .
26 January 2026


Managing Director



Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
CONSOLIDATED STATEMENT OF CASH FLOWS (Unaudited)
For the Half-Year ended 31 December 2025

	Amount in Taka	
	Half-year ended 31.12.2025	Half-year ended 31.12.2024
Cash Flows From Operating Activities:		
Received from revenue and others	7,434,376,470	5,933,704,334
Payment for operation, expenses & others	(6,537,838,174)	(5,280,487,091)
Miscellaneous income	393,827	903,243
Cash generated from operations	896,932,123	654,120,486
Income tax paid	(78,552,144)	(78,685,686)
Payment for Financial charges	(50,506,436)	(36,620,120)
Net cash provided by operating activities	767,873,543	538,814,680
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(1,367,008,049)	(387,287,968)
Acquisition of financial assets	(30,689,402)	90,643,806
Received from bank	1,933,524	3,643,126
Net cash used in investing activities	(1,395,763,927)	(293,001,036)
Cash Flows From Financing Activities:		
Payment of dividend	(169,345,162)	(157,920,405)
Payment of lease liabilities	(14,923,915)	(14,486,825)
Long term finance received/(paid) from bank (Net)	10,072,607	178,424,544
Transactions Non Controlling Interests	35,000,000	-
Short term finance received/(paid) from bank (Net)	784,004,937	(336,367,661)
Net cash provided by financing activities	644,808,467	(330,350,348)
Increase/(decrease) in cash and cash equivalents	16,918,084	(84,536,704)
Cash and cash equivalents at 1 July	314,903,147	365,229,893
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	3,423,332	(46,902)
Cash and cash equivalents at 31 December	335,244,563	280,646,287
NOCFPS (Note 32.A)	24.58	17.25


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF FINANCIAL POSITION (Unaudited)

As at 31 December 2025

		Amount in Taka	
		31 December 2025	30 June 2025
ASSETS:			
Non-Current Assets:			
		5,881,757,434	4,710,090,479
Property, Plant and Equipment	04	2,366,630,147	2,431,653,536
Capital Work-In-Progress	05	2,330,923,943	1,155,822,174
Right-of-Use Assets	05.B	20,670,445	33,072,711
Financial Assets	06	11,702,429	17,657,518
Advances, Deposits & Prepayments	10.1	8,661,000	33,715,070
Investment in Subsidiaries	07	1,143,169,470	1,038,169,470
Current Assets :		2,662,526,609	2,424,153,681
Financial Assets	07.A	59,144,491	22,500,000
Inventories	08	1,666,894,004	1,603,775,310
Trade and Other Receivables	09	215,741,026	187,596,187
Advances, Deposits & Prepayments	10.1	530,686,715	429,600,396
Cash & Cash Equivalents	11	190,060,372	180,681,788
TOTAL ASSETS		8,544,284,043	7,134,244,160
SHAREHOLDERS' EQUITY AND LIABILITIES:			
Shareholders' Equity:			
		4,195,293,329	3,932,383,056
Share Capital	12	312,436,270	312,436,270
Tax Holiday Reserve	13	4,392,110	4,392,110
FVOCI Reserve	14	(20,903,911)	(15,544,331)
Retained Earnings	15	3,899,368,860	3,631,099,007
LIABILITIES:			
Non-Current Liabilities:		866,233,075	848,925,369
Long Term Finance	16	765,988,631	753,223,072
Employee Benefit Obligations	17	1,629,086	990,546
Deferred Tax Liabilities	18	98,615,358	94,711,750
Current Liabilities:		3,482,757,640	2,352,935,735
Short Term Finance	20	1,776,539,472	933,771,898
Current Portion of Long Term Finance	21	59,746,323	119,445,855
Lease Liabilities	17.B	9,820,926	23,798,698
Trade and Other Payables	22	975,645,837	775,229,847
Unclaimed Dividend	22.B	72,718,559	42,104,508
Provision for Corporate Tax	23	588,286,523	458,584,929
TOTAL SHAREHOLDERS' EQUITY AND LIABILITIES		8,544,284,043	7,134,244,160
Net Assets Value (NAV) Per Share		31	125.86

Chief Financial Officer

Company Secretary

Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME (Unaudited)
For the Half-Year ended 31 December 2025

Amount in Taka					
Notes	For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)	For the Quarter (1 October 2025 to 31 December 2025)	For the Quarter (1 October 2024 to 31 December 2024)	
REVENUE	24	6,656,319,403	5,409,918,654	3,342,272,340	2,866,113,043
Cost of goods sold	24.B	(3,961,391,054)	(3,223,746,603)	(2,010,436,948)	(1,724,667,639)
GROSS PROFIT		2,694,928,349	2,186,172,051	1,331,835,392	1,141,445,403
OPERATING EXPENSES		(2,030,209,497)	(1,651,927,422)	(1,000,249,895)	(840,941,016)
Administrative expenses	25	(102,360,646)	(112,648,751)	(47,403,485)	(62,985,465)
Selling & Distribution expenses	26	(1,927,848,851)	(1,539,278,671)	(952,846,410)	(777,955,552)
OPERATING PROFIT		664,718,853	534,244,629	331,585,498	300,504,387
Finance charges	34	(51,452,579)	(38,753,623)	(24,745,892)	(20,151,925)
Other income		18,034,423	8,366,101	8,586,211	1,735,641
Profit before WPPF and welfare fund		631,300,696	503,857,107	315,425,816	282,088,103
Workers' P.P. fund and welfare fund	27	(30,061,938)	(23,993,196)	(15,020,277)	(13,432,767)
PROFIT BEFORE TAX		601,238,759	479,863,911	300,405,540	268,655,336
Income tax expenses	28	(133,009,692)	(112,936,413)	(47,549,184)	(43,786,633)
PROFIT FOR THE PERIOD		468,229,066	366,927,499	252,856,355	224,868,703
Other Comprehensive Income:					
Change in fair value of Marketable Securities	29	(5,955,089)	(3,056,462)	(9,259,763)	2,177,588
Less: Deferred tax		595,509	305,646	925,976	(217,759)
Total other comprehensive income for the period, net of tax		(5,359,580)	(2,750,816)	(8,333,787)	1,959,829
Total Comprehensive Income for the period		462,869,486	364,176,683	244,522,568	226,828,533
Earnings Per Share (EPS)	30	14.99	11.74	7.83	7.26
Number of Shares used to Compute EPS		31,243,627	31,243,627	31,243,627	31,243,627


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC

STATEMENT OF CHANGES IN EQUITY (Unaudited)

For the Half-Year ended 31 December 2025

Amount in Taka


Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,493
Statement of profit or loss and other Comprehensive Income-2024-25			(6,933,611)	660,162,024	653,228,413
Dividend for the year 30 June, 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 30 June 2025	312,436,270	4,392,110	(15,544,332)	3,631,099,007	3,932,383,056
Statement of profit or loss and other Comprehensive Income for period ended 31 December 2025			(5,359,580)	468,229,066	462,869,486
Dividend for the year 30 June, 2025 (Cash-64%)				(199,959,213)	(199,959,213)
Balance as at 31 December 2025	312,436,270	4,392,110	(20,903,912)	3,899,368,860	4,195,293,329

STATEMENT OF CHANGES IN EQUITY (Unaudited)


For the Half-Year ended 31 December 2024

Amount in Taka

Particulars	Paid up Capital	Tax Holiday Reserve	FVOCI Reserve	Retained Earnings	Total
Balance as at 1 July 2023	312,436,270	4,392,110	(2,266,352)	2,700,165,629	3,014,727,658
Statement of profit or loss and other Comprehensive Income for period ended 30 June 2024			(6,344,369)	655,067,965	648,723,597
Dividend for the period 30 June 2023 (Cash - 60%)				(187,461,762)	(187,461,762)
Balance as at 30 June 2024	312,436,270	4,392,110	(8,610,721)	3,167,771,833	3,475,989,493
Statement of profit or loss and other Comprehensive Income for period ended 31 December 2024			(2,750,816)	366,927,499	364,176,683
Dividend for the year 30 June 2024 (Cash-63%)				(196,834,850)	(196,834,850)
Balance as at 31 December 2024	312,436,270	4,392,110	(11,361,537)	3,337,864,481	3,643,331,325



Chief Financial Officer


Company Secretary


Director


Dated, Dhaka .
26 January 2026


Managing Director



Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
STATEMENT OF CASH FLOWS (Unaudited)
For the Half-Year ended 31 December 2025

	Amount in Taka	
	Half-year ended 31.12.2025	Half-year ended 31.12.2024
Cash Flows From Operating Activities:		
Received from revenue and others	6,628,174,563	5,402,228,789
Payment for operation, expenses & others	(5,753,766,978)	(4,782,358,826)
Miscellaneous income	393,827	903,243
Cash generated from operations	874,801,412	620,773,206
Income tax paid	(74,449,586)	(76,940,255)
Payment for Financial charges	(50,506,436)	(36,620,120)
Net cash provided by operating activities	749,845,390	507,212,831
Cash Flows From Investing Activities:		
Acquisition of property, plant and equipment	(1,221,421,783)	(290,501,594)
Investment in Subsidiary	(105,000,000)	(50,000,000)
Acquisition of financial assets	(30,689,402)	69,865,491
Received from bank	1,656,524	
Net cash used in investing activities	(1,355,454,661)	(270,636,103)
Cash Flows From Financing Activities:		
Payment of dividend	(169,345,162)	(157,920,405)
Payment of lease liabilities	(14,923,915)	(14,306,825)
Long term finance received/(paid) from bank (Net)	12,765,558	88,590,529
Short term finance received/(paid) from bank (Net)	783,068,041	(244,359,331)
Net cash provided by financing activities	611,564,522	(327,996,033)
Increase/(decrease) in cash and cash equivalents	5,955,252	(91,419,305)
Cash and cash equivalents at 1 July	180,681,788	312,475,845
Foreign Exchange Fluctuation Gain/(Loss) on FCAD ERQ Accounts	3,423,332	(46,902)
Cash and cash equivalents at 31 December	190,060,372	221,009,638
NOCFPS (Note 32)	24.00	16.23



Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman

THE IBN SINA PHARMACEUTICAL INDUSTRY PLC
SELECTED NOTES TO THE FINANCIAL STATEMENTS (UNAUDITED)
For the Half-Year ended 31 December 2025

SELECTED EXPLANATORY NOTES:

1.1 The company and the group

The IBN SINA Pharmaceutical Industry PLC (the "Company") was incorporated in Bangladesh on 22 December 1983 under the Companies Act, 1913 (replaced by the Companies Act 1994) and it was converted into a Public Limited Company in 1989.

The registered office of the company is at Tanin Center, 3 Asad Gate, Mirpur Road, Mohammadpur, Dhaka-1207. The Company is listed with Dhaka Stock Exchange Limited (DSE) and Chittagong Stock Exchange Limited (CSE).

As the 99.99% shareholder of The IBN SINA API Industry Ltd., 99.99% The IBN SINA Natural Medicine Ltd. and 65% The IBN SINA Polymer Industry Ltd., The IBN SINA Pharmaceutical Industry PLC started its operation as a group company from 16 September 2019. Hereinafter it is referred as the group as and where applicable for the purpose of preparing consolidated financial statements.

1.2 Nature of business

The Company involves in production of pharmaceutical drugs and natural medicines and selling them in both local and international market.

2 Basis of preparation

2.1 Statement of compliance

These interim financial statements have been prepared in accordance with the International Accounting Standard IAS 34: Interim Financial Reporting, the Companies Act 1994, the Securities and Exchange Rules 2020, Financial Reporting Act 2015, relevant guidelines issued by Bangladesh Securities and Exchange Commission ("BSEC") and other applicable laws and regulations in Bangladesh.

The financial statements have been prepared on a historical cost basis, except for financial assets that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on going concern basis. The interim financial statements should be read in conjunction with The IBN SINA Pharmaceutical Industry PLC's annual statutory financial statements as at 30 June 2025.

2.2 Date of authorisation

The interim financial statements were authorised for issue by the Board of Directors on 26 January 2026 for publication.

2.3 Functional and presentation currency

The financial statements are presented in Bangladeshi Taka (BDT), which is both functional and presentation currency of The IBN SINA Pharmaceutical Industry PLC.

2.4 Significant accounting policies

The same accounting policies and methods of computation have been followed in these interim financial statements as were applied in the preparation of the audited financial statements of The IBN SINA Pharmaceutical Industry PLC as at and for the year ended 30 June 2025.

3 Significant Deviations

3.1 EARNINGS PER SHARE (EPS):

Earnings per share has been calculated based on number of shares outstanding for the period ended 31 December 2025 and profit for the same period. The number of shares outstanding for the period was 31,243,627. Earnings per share for the corresponding period of 2024 has also been calculated based on 31,243,627 shares. No diluted earnings per share is required to be calculated as there was no scope for dilution during the period under review.

3.2 SUBSEQUENT EVENTS:

No material events occurred after the reporting date, non disclosure of which could affect the stakeholders to make proper valuation and decision.

3.3 INCREASE IN EARNINGS PER SHARE (EPS):

As a result of increase in Sales , EPS has been increased during current period over last reporting period.

3.4 INCREASE IN NET OPERATING CASH FLOW PER SHARE (NOCFPS):

Net operating cash flow per share (NOCFPS) increased during current period over last reporting period due to decrease in payment for cost & expenses & others.

3.5 INCOME TAX:

Payment of income tax decreased due to decrease in tax rate and net profit. advance income tax also increased due to payment for quarterly installment.

3.6 PAYMENT FOR FIXED ASSETS:

Payment for purchases of fixed assets increased due to increase in addition of fixed assets during this reporting period.

3.7 Other income increased during the period due to increase in revenue from toll production charge.

3.8 Payment of dividend increased due to declaration of higher dividend on last year's income during the reporting period.

3.9 FINANCE CHARGE:

Finance charge during the reporting period increased due to increase of long term loan.

3.10 INCREASE IN REVENUE:

The main objective of the company is to increase revenue which is essential for survival in the market. Due to increase in demand for the company's product in market, revenue has been increased during current period over last reporting period.

3.11 CASH FLOWS FROM INVESTING ACTIVITIES:

Cash flows from investing activities increased during the reporting period due to increased payment made for purchase of fixed assets and payment of share capital of The IBN SINA API Industry Ltd. And The IBN SINA Polymer Industry Ltd. than the same period of last year.

3.12 SHORT TERM FINANCE:

Short term finance increased during the period due to increase in import of raw materials under sight LC arrangement.

3.13 Previous period figures have been re-arranged to conform to current period presentation, where considered necessary.

	31 December 2025	30 June 2025
04. PROPERTY, PLANT AND EQUIPMENT:		
Cost :		
Opening balance	4,169,069,419	3,956,915,644
Addition during the period	22,724,976	215,232,652
Disposal/Adjustment during the period	-	(3,078,877)
Closing balance	4,191,794,395	4,169,069,419
Accumulated Depreciation:		
Opening balance	1,737,415,882	1,554,782,910
Charged during the period	87,748,365	185,554,095
Disposal/Adjustment during the period	-	(2,921,123)
Closing balance	1,825,164,247	1,737,415,883
Closing balance of written Down Value (WDV)	2,366,630,147	2,431,653,536

The factory land and land development (803 decimal) and building are pledged as security for long term and short term bank finance of the company.

04 A. CONSOLIDATED PROPERTY, PLANT AND EQUIPMENT:		
The IBN SINA Pharmaceutical Industry PLC	2,366,630,147	2,431,653,536
The IBN SINA API Industry Ltd.	167,949,699	142,245,156
The IBN SINA Natural Medicine Ltd.	78,259,172	79,332,838
The IBN SINA Polymer Industry Ltd.	2,518,673	2,288,106
	2,615,357,691	2,655,519,636
05. CAPITAL WORK-IN-PROGRESS:		
A) Construction work-in-progress (Building)		
Opening balance	711,323,283	366,379,612
Addition during the period	100,659,855	344,943,671
Less: Transferred to property plant and equipment	-	-
Closing balance	811,983,138	711,323,283
B) Machinery in transit and installation		
Opening balance	398,469,652	213,664,954
Addition during the period	1,098,036,952	310,149,835
Less: Transferred to property, plant and equipment	-	(125,345,137)
	1,496,506,604	398,469,652
C) Other Goods-In-Transit	22,434,201	46,029,239
	2,330,923,943	1,155,822,174

i) Some new construction is under process to increase the overall production capacity of The IBN SINA Pharmaceutical Industry PLC. The amount in machinery in transit represents the amount for opening the LC for the procurement of Factory machineries for newly constructed factory building and increasing production capacity of existing factory which are not received yet by the company.

05.A CONSOLIDATED CAPITAL WORK-IN-PROGRESS:		
A) Construction work-in-progress (Building)		
Opening balance	939,492,119	465,469,776
Addition during the period	182,921,796	474,022,343
Less: Transferred to property plant and equipment	-	-
Closing balance	1,122,413,915	939,492,119
B) Machinery in transit and installation		
Opening balance	946,837,388	673,427,435
Addition during the period	1,128,344,369	398,755,090
Less: Transferred to property, plant and equipment	-	(125,345,137)
Closing balance	2,075,181,757	946,837,388
Other Goods-In-Transit	22,434,201	46,029,239
	3,220,029,873	1,932,358,746

		Amount in Taka	
		31 December 2025	30 June 2025
05.B RIGHT-OF-USE ASSETS:			
Opening balance		130,252,602	130,252,602
Addition during the period		-	-
Disposal/Adjustment during the period		-	-
Closing balance		130,252,602	130,252,602
Accumulated Depreciation:			
Opening balance		97,179,890	72,375,357
Addition during the period		12,402,267	24,804,533
Disposal/Adjustment during the period		-	-
Closing balance		109,582,157	97,179,890
Closing balance of Written Down Value (WDV)		20,670,445	33,072,711
06. FINANCIAL ASSETS (NON-CURRENT PORTION):			
Exim Bank PLC		1,140,000	2,090,000
First Security Islami Bank PLC		3,896,900	7,793,800
Shahjalal Islami Bank PLC		1,699,500	1,699,500
Al-Arafah Islami Bank PLC		1,622,250	1,849,365
Social Islami Bank PLC		520,929	1,284,958
Islami Bank Bangladesh PLC (IBBL) in MPB		2,822,850	2,939,895
		11,702,429	17,657,518
The above investment in marketable securities are designated as Fair Value through Other Comprehensive Income (FVOCI) by the management. These are measured at fair value and presented as non-current asset. Unrealized gain/(loss) from the above investment were recognized in other comprehensive income. The shares of Exim Bank PLC and IBBL-MPB are listed in Dhaka Stock Exchange PLC and Chittagong Stock Exchange PLC. The whole investment in shares of both the companies are in DSE only.			
06.A CONSOLIDATED FINANCIAL ASSETS (NON-CURRENT PORTION):			
Exim Bank PLC		1,140,000	2,090,000
First Security Islami Bank PLC		3,896,900	7,793,800
Shahjalal Islami Bank PLC		1,699,500	1,699,500
Al-Arafah Islami Bank PLC		1,622,250	1,849,365
Social Islami Bank PLC		520,929	1,284,958
Islami Bank Bangladesh PLC (IBBL) in MPB		2,822,850	2,939,895
Investment in API Industrial Park Services Ltd.		29,000,000	29,000,000
		40,702,429	46,657,518
07 INVESTMENT IN SUBSIDIARIES :			
The IBN SINA API Industry Ltd.		709,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.		238,169,670	238,169,670
The IBN SINA Polymer Industry Ltd.		195,000,000	130,000,000
		1,143,169,470	1,038,169,470
i) The IBN SINA API Industry Ltd. is a 99.99% owned subsidiary company. Tk. 4 crore have been paid as a part of share capital.			
ii) The IBN SINA Natural Medicine Ltd. is a 99.99% owned subsidiary company.			
iii) The IBN SINA Polymer Industry Ltd. is a 65% owned subsidiary company. Tk. 6.5 crore have been paid as a part of share capital.			
07.A FINANCIAL ASSETS (CURRENT PORTION):			
Opening balance (Investment in MTD)		22,500,000	89,500,000
During the period/year		36,644,491	-
MTDR-Closed during the period		-	(67,000,000)
Investment in Mudaraba Term Deposit		59,144,491	22,500,000
MTDR amount in Tk.36,644,491 is restricted for LC security purpose.			
07.B CONSOLIDATED FINANCIAL ASSETS (CURRENT PORTION):			
Opening Balance		22,500,000	22,500,000
During the period/year		36,644,491	-
Investment in Mudaraba Term Deposit		59,144,491	22,500,000

Amount in Taka

08. INVENTORIES:

	31 December 2025	30 June 2025
Raw materials	677,068,657	661,133,854
Packing materials	245,972,884	230,992,875
Work-in-process	118,133,623	97,983,312
Finished goods	367,714,938	357,701,249
Physicians' samples	5,960,322	5,836,177
Pad & literature	4,290,300	4,127,335
Spares & stores	387,044	360,234
Indirect materials	468,148	463,694
Printing & stationery	406,128	393,698
Laboratory chemicals	237,779	236,318
Material in transit	246,254,181	244,546,564
	<u>1,666,894,004</u>	<u>1,603,775,310</u>

i) The inventory quantity can not be disclosed as some of material contain in liter, some are in pieces, some are in box and some are in kg, gram, milli gram, ton, liter and pcs as such quantity can not be inserted.

ii) There is no damage goods or slow moving item in the inventory list.

iii) As part of loan condition all of the company's inventory are pledged as security for loan finance of the company.

iv) Inventory for raw materials, packing materials, Work In Process, Finished goods and material in transit increased during the period for ensuring smooth supply of goods to meetup increased customer demand.

08.A CONSOLIDATED INVENTORIES:

Raw materials	761,297,623	768,094,729
Packing materials	279,990,940	245,848,438
Work-in-process	130,897,989	111,124,876
Finished goods	450,647,310	424,409,351
Physicians' samples	8,830,939	8,481,886
Pad & literature	4,290,300	4,127,335
Spares & stores	387,044	360,234
Indirect materials	468,148	463,694
Printing & stationery	406,128	393,698
Laboratory chemicals	237,779	236,318
Material in transit	246,254,181	244,546,564
	<u>1,883,708,381</u>	<u>1,808,087,123</u>

09. TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	209,382,707	181,402,168
Receivable from provident fund (PF)	304,966	304,966
Profit receivable from MTD	1,666,635	3,391,971
Other receivable-toll charge	4,386,718	2,497,081
	<u>215,741,026</u>	<u>187,596,187</u>

i) Amount are receivables from customers mainly different hospitals, medical colleges, clinics, diagnostic centers. No amount was due by the directors (including the Managing Director), managers and other officers of the company or any of them either severally or jointly with any other person.

ii) Other receivable increased during the period due to increased toll charge.

iii) Trade receivable increased during the period due to increase in sales revenue and customer types.

09.A CONSOLIDATED TRADE AND OTHER RECEIVABLES:

Trade receivable (net off bad debt provision)	220,487,569	189,858,588
Receivable from provident fund (PF)	304,966.00	304,966
Profit receivable from MTD	1,666,635	3,391,971
Other receivable-toll charge	4,386,718	2,497,081
	<u>226,845,888</u>	<u>196,052,607</u>

		Amount in Taka	
		31 December 2025	30 June 2025
10. ADVANCES, DEPOSITS AND PREPAYMENTS :			
a. Advances against			
Salary	7,001,705	5,482,341	
Expenses/works/others	12,380,214	12,433,414	
Depot rent	6,858,981	6,727,985	
Motor cycles-to employees	42,563,988	42,143,838	
Others	697,768	706,533	
	<u>69,502,656</u>	<u>67,494,111</u>	
b. Income tax			
Opening balance	374,539,128	200,028,807	
Addition	74,449,586	174,510,320	
Adjusted during the period			
	<u>448,988,713</u>	<u>374,539,128</u>	
c. Deposits			
Security money	20,856,322	21,275,544	
d. Pre payments			
Value Added Tax	23	6,683	
	<u>539,347,715</u>	<u>463,315,466</u>	
10.1 MATURITY ANALYSIS:			
Realizable/adjustable within one year.	530,686,715	429,600,396	
Realizable/adjustable after one year.	8,661,000	33,715,070	
	<u>539,347,715</u>	<u>463,315,466</u>	
10.A CONSOLIDATED ADVANCES, DEPOSITS AND PREPAYMENTS :			
a. Advances against			
Salary	11,471,975	9,555,942	
Expenses/works/others	13,339,998	31,119,648	
Depot rent	6,858,981	6,727,985	
Motor cycles-to employees	56,524,029	61,431,738	
Others	2,590,291	2,101,636	
	<u>90,785,274</u>	<u>110,936,949</u>	
b. Income tax			
Opening balance	404,148,716	223,481,751	
Addition	78,552,144	180,666,965	
Adjusted during the period			
	<u>482,700,860</u>	<u>404,148,716</u>	
c. Deposits			
Security money	21,911,019	22,330,241	
d. Pre payments			
Value Added Tax	23	6,683	
	<u>595,397,177</u>	<u>537,422,590</u>	
The company did not give any advance, deposit and prepayment to the director's of the company, subsidiaries and other connected parties and employees advances are realised in normal course of business.			
10.A.1 MATURITY ANALYSIS:			
Realizable/adjustable within one year.	586,486,178	503,707,520	
Realizable/adjustable after one year.	8,911,000	33,715,070	
	<u>595,397,178</u>	<u>537,422,590</u>	
11. CASH AND CASH EQUIVALENTS:			
a. Cash in hand	8,137,054	6,613,494	
b. Cash at bank	178,383,318	170,528,294	
c. Imprest cash	3,540,000	3,540,000	
	<u>190,060,372</u>	<u>180,681,788</u>	

		Amount in Taka	
		31 December 2025	30 June 2025
11.A CONSOLIDATED CASH AND CASH EQUIVALENTS:			
a. Cash in hand		9,479,502	7,137,453
b. Cash at bank		322,095,061	304,095,694
c. Imprest cash		3,670,000	3,670,000
		<u>335,244,563</u>	<u>314,903,147</u>
12. SHARE CAPITAL:			
Authorized:			
50,000,000 Ordinary Shares of Tk. 10 each		<u>500,000,000</u>	<u>500,000,000</u>
Issued, Subscribed & Paid-Up :			
31,243,627 Ordinary Shares of Tk. 10 each fully paid up in cash		<u>312,436,270</u>	<u>312,436,270</u>
The Shareholdings consist of :			
Holders	No. of Holders	Total Holdings	Percentage
Sponsors	1	13,843,312	44.31%
Institution (I.C.B)	207	7,624,427	24.40%
General Public	12,157	9,775,888	31.29%
	<u>12,365</u>	<u>31,243,627</u>	<u>100.00%</u>
The distribution schedule showing the number of share holders and their share holdings as on 30.12.2024 are as follows:			
Range of Holdings	No. of Holders	Total Holdings	Percentage
Less than 500 shares	9,750	1,736,642	5.97%
500 to 5,000 shares	2,234	3,333,683	11.36%
5,001 to 10,000 shares	194	1,411,886	4.69%
10,001 to 20,000 shares	90	1,211,208	4.73%
20,001 to 30,000 shares	28	655,673	2.98%
30,001 to 40,000 shares	10	355,707	2.00%
40,001 to 50,000 shares	14	642,700	1.83%
Above 50,000 shares	45	21,896,128	66.43%
	<u>12,365</u>	<u>31,243,627</u>	<u>100.00%</u>
The shares are listed with the Dhaka Stock Exchange Limited and Chittagong Stock Exchange PLC The shares were quoted at Tk.314 in the Dhaka Stock Exchange PLC on 30.12.2025 and at Tk.315.00 in the Chittagong Stock Exchange Limited on 30.12.2025 respectively.			
13. TAX HOLIDAY RESERVE:		<u>4,392,110</u>	<u>4,392,110</u>
This represents provision made out of profit of Tax Holiday period in accordance with section 45 (2B) and section 46A (2) of Income Tax Ordinance 1984.			
14. FAIR VALUE THROUGH OTHER COMPREHENSIVE INCOME (FVOCI) RESERVE:			
Closing market value of marketable securities		11,702,429	17,657,518
Less: Cost of marketable securities		34,928,997	34,928,997
Unrealized gain before adjustment of deferred tax		<u>(23,226,568)</u>	<u>(17,271,479)</u>
Less: Deferred tax on unrealized gain/(loss)		2,322,657	1,727,148
Net unrealized gain/(loss) on marketable securities		<u>(20,903,911)</u>	<u>(15,544,331)</u>
15. RETAINED EARNINGS:			
Opening Balance		3,631,099,007	3,167,771,833
Dividend paid		(199,959,213)	(196,834,850)
Add : Net profit during the period		468,229,066	660,162,024
		<u>3,899,368,860</u>	<u>3,631,099,007</u>
15A. CONSOLIDATED RETAINED EARNINGS:			
Opening Balance		3,625,617,615	3,189,263,114
Dividend paid		(199,959,213)	(196,834,850)
Add: Net profit during the period		477,914,529	633,189,350
		<u>3,903,572,930</u>	<u>3,625,617,615</u>
15B. NON CONTROLLING INTERESTS:			
The IBN SINA API Industry Ltd.		200	200
The IBN SINA Natural Medicine Ltd.		3,000	3,000
The IBN SINA Polymer Industry Ltd. (Paid by IBN SINA Trust)		105,000,000	70,000,000
Add: Share of Profit/(Loss)		259,984	943,396
		<u>105,263,184</u>	<u>70,946,596</u>

		Amount in Taka	
		31 December 2025	30 June 2025
16. LONG TERM FINANCE :			
i) From Al-Arafah Islami Bank PLC. Secured (Under Hire Purchase Shirkatul Melk-HPSM)		505,481,423	565,545,640
ii) From Pubali Bank PLC (Long Term -H.P.S.M) Pharma		320,230,135	307,123,287
Current maturity transferred to current liability			
iii) From Al-Arafah Islami Bank PLC Secured (Under Hire Purchase Shi Note -21		(59,722,928)	(119,445,855)
LONG TERM FINANCE - net off current maturity		765,988,631	753,223,072
i) Loan amount represent the amounts which would be due for repayment after 12 (twelve) months from the date of Statement of Financial Position @ 12.50% of profit.			
ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import capital machinery and motor vehicle under Hire Purchase Shirkatul Melk.			
iii) HPSM is repayable in 84 monthly equal installment.			
iv) Currently all of the company's HPSM and other loans are classified as standard by the Bank.			
v) Information regarding loan fall due after five years.			
Loan fall due from 2 to 5 years		336,987,615	377,030,427
Loan fall due from 6 to more years		429,001,015	376,192,645
		765,988,631	753,223,072
16.A CONSOLIDATED LONG TERM FINANCE :			
The IBN SINA Pharmaceutical Industry PLC		765,988,631	753,223,072
The IBN SINA API Industry Ltd.		218,789,352	221,482,304
		984,777,983	974,705,376
17. EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		990,546	1,185,180
Provision during the period		74,300,000	97,491,986
Less: Paid during the period		(73,661,460)	(97,686,620)
		1,629,086	990,546
17. A CONSOLIDATED EMPLOYEE BENEFIT OBLIGATIONS:			
Opening Balance		990,546	1,185,180
Provision during the period		96,167,189	137,250,512
Less: Paid during the period		(95,528,649)	(137,445,146)
		1,629,086	990,546
17. B LEASE LIABILITIES:			
Opening Balance		23,798,698	50,336,979
Finance charge		946,143	3,692,459
Paid during the period		(14,923,915)	(30,230,740)
Closing balance		9,820,926	23,798,698
Less : Transferred to current maturity		(9,820,926)	(23,798,698)
		-	-
i) The company has lease against its head office and its training center located at Mohammadpur, Dhaka.			
ii) Lease period is upto 31.10.2026			
iii) Monthly rental payment is Tk.1,851,270			
iv) Advance amount paid Tk. 11,661,000			
v) Monthly advance adjustment Tk. 50,000			

Amount in Taka

31 December 2025	30 June 2025
------------------	--------------

18. DEFERRED TAX LIABILITY:

Deferred tax assets and liabilities have been recognized and measured in accordance with the provisions of IAS 12 Income Taxes. Related deferred tax expense/(income) have been disclosed in note 19. The components of deferred tax assets and liabilities are given below:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,366,630,147	1,861,008,772	505,621,375	20.00%	101,124,275
Gratuity	75,290,547	73,661,460	(1,629,087)	20.00%	(325,817)
Lease	10,849,519	10,151,733	697,786	20.00%	139,557
Unrealized gain on marketable securities	(23,226,568)	-	(23,226,568)	10.00%	(2,322,657)
As at 31 December 2025	2,429,543,645	1,944,821,965	481,463,507		98,615,358
Property, plant and equipment	2,431,653,536	1,943,389,552	488,263,984	20.00%	97,652,797
Gratuity	98,677,167	97,686,620	(990,547)	20.00%	(198,109)
Lease	9,274,013	12,994,333	(3,720,320)	20.00%	(744,064)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,523,691,863	2,054,070,505	464,923,013		94,711,750

DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	98,615,358	94,711,750
Opening balance of deferred tax liability	94,711,750	99,285,702
Total deferred tax expenses/(income)	3,903,608	(4,573,952)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(595,509)	770,401
	3,308,099	(3,803,551)

19 CONSOLIDATED DEFERRED TAX LIABILITY:

Particulars	Carrying amount	Tax base value	Taxable (deductible) temporary difference	Applicable tax rate	Deferred tax liability
Property, plant and equipment	2,612,839,018	2,099,214,999	513,624,019	20% to 30%	103,078,547
Gratuity	75,290,547	73,661,460	(1,629,087)		(325,817)
Lease	10,498,840	10,151,733	347,107		43,120
Unrealized gain on marketable securities	(23,226,568)	-	(23,226,568)	10.00%	(2,322,657)
As at 31 December 2025	2,675,401,837	2,183,028,192	489,115,472		100,473,193
Property, plant and equipment	2,653,231,530	2,157,701,612	495,529,918	20% to 27.50%	99,530,336
Gratuity	148,665,292	147,674,745	(990,547)		(198,109)
Lease	8,813,099	12,994,333	(4,181,234)		(870,815)
Unrealized gain on marketable securities	(17,271,479)	-	(17,271,479)	10.00%	(1,727,148)
Bad Debt provision	1,358,626	-	(1,358,626)	20.00%	(271,725)
As at 30 June 2025	2,794,797,068	2,318,370,690	471,728,032		96,462,538

CONSOLIDATED DEFERRED TAX EXPENSES/(INCOME) :

Closing balance of deferred tax liability	100,473,193	96,462,538
Opening balance of deferred tax liability	96,462,538	101,180,185
Total deferred tax expenses/(income)	4,010,655	(4,717,647)
Less: Deferred tax (income)/ expenses related to other comprehensive income	(595,509)	770,401
	3,415,146	(3,947,246)

20. SHORT TERM FINANCE :

A. From Al-Arafah Islami Bank PLC - Secured (Under Composite facilities LC(MPI/TR/UPAS)	1,776,539,472	933,771,898
	1,776,539,472	933,771,898

i) Loan amount represent the amounts which would be due for repayment within 12 (twelve) months from the date of Statement of Financial Position @ 12.50% of profit and 0.25% commission per quarter to be paid.

ii) The loan was taken from Al-Arafah Islami Bank PLC against mortgage of 803 decimal land and 63,811 square feet factory building located at Shafipur, Gazipur to import Pharmaceuticals raw materials, imported goods and to purchase business items from local market under Composite facilities LC/MPI/MPI TR/UPAS/ Baimuajjal agreement.

iii) Short term loan is repayable with in twelve months.

iv) Currently all of the company's MPI/UPAS and other loans are classified as standard by the Bank.

		Amount in Taka	
		31 December 2025	30 June 2025
20.A CONSOLIDATED SHORT TERM FINANCE :			
A. From Al-Arafah Islami Bank Ltd. - Secured		1,776,539,472	933,771,898
(Under Composite facilities LC(MPI/TR/UPAS))			
B. The IBN SINA API Industry Ltd.		20,848,237	19,911,341
		<u>1,797,387,709</u>	<u>953,683,239</u>
21. CURRENT PORTION OF LONG TERM FINANCE:			
i) From Al-Arafah Islami Bank PLC-Secured		59,746,323	119,445,855
(Under Hire Purchase Shirkatul Melk)			
The amounts represent current maturity of long term finance obtained from Al-Arafah Islami Bank PLC and lease liability which are repayable within next 12 (Twelve) months from the date of Statement of Financial Position.			
22. TRADE AND OTHER PAYABLES:			
Payable to suppliers		527,462,373	354,248,263
Provisions	Note-22.1	154,559,435	187,977,710
Accrued expenses		252,384,120	178,532,052
Security money received from employees and others		11,177,972	11,517,972
Workers' profit participation fund & welfare fund		30,061,938	42,953,850
		<u>975,645,837</u>	<u>775,229,847</u>
22.1 PROVISIONS:			
Opening balance		187,977,710	144,607,133
Provisions made during the period		154,559,435	187,977,710
Provisions used during the period		(187,977,710)	(144,607,133)
Closing balance		<u>154,559,435</u>	<u>187,977,710</u>
22.A CONSOLIDATED TRADE AND OTHER PAYABLES :			
Payable to suppliers		568,508,781	396,181,410
Provisions		154,559,435	187,977,710
Accrued expenses		262,260,925	203,253,644
Security money received from employees and others		11,177,972	11,517,972
Workers' profit participation fund & welfare fund		32,129,881	43,358,391
		<u>1,028,636,994</u>	<u>842,289,127</u>
Payable to suppliers increased during the period to meet business need.			
22.B UNCLAIMED DIVIDEND :			
Opening		42,104,508	39,140,597
Addition		199,959,213	196,834,850
Paid to share holders		(169,345,162)	(186,963,608)
Paid to Capital Market Stabilisation Fund		-	(6,907,331)
		<u>72,718,559</u>	<u>42,104,508</u>
22.2 UNCLAIMED DIVIDEND :			
2021-22		10,214,969	12,953,290
2022-23		14,205,187	15,606,678
2023-24		12,854,100	13,544,540
2024-25		35,444,302	-
		<u>72,718,559</u>	<u>42,104,508</u>
23. PROVISION FOR CORPORATE TAX:			
Opening balance		458,584,929	255,866,409
Current tax provision		129,701,593	202,718,520
		<u>588,286,523</u>	<u>458,584,929</u>
23.A CONSOLIDATED INCOME TAX PAYABLES:			
Opening balance		495,245,930	284,580,559
Current tax expense		141,903,654	210,665,371
		<u>637,149,585</u>	<u>495,245,930</u>


		Amount in Taka	
		For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
24. REVENUE:			
Local revenue		6,568,191,774	5,311,628,119
Export revenue		88,127,629	98,290,535
		6,656,319,403	5,409,918,654
24.A CONSOLIDATED REVENUE:			
The IBN SINA Pharmaceutical Industry PLC		6,656,319,403	5,409,918,654
The IBN SINA Natural Medicine Ltd		808,850,349	520,127,637
		7,465,169,752	5,930,046,291
24.B COST OF GOODS SOLD :			
Materials		3,251,068,111	2,675,262,571
Factory Overhead		643,015,437	478,077,285
Depreciation		67,307,505	70,406,748
		3,961,391,054	3,223,746,603
24.C CONSOLIDATED COST OF GOODS SOLD :			
Materials		3,602,706,143	2,901,518,093
Factory Overhead		740,716,398	558,697,069
Depreciation		70,487,738	73,813,668
		4,413,910,280	3,534,028,829
25. ADMINISTRATIVE EXPENSES :			
Salary, Wages & Allowances		63,820,044	63,567,515
Repairs & Maintenance		4,475,641	9,072,702
Travelling & Conveyance		4,378,621	2,627,748
AGM, Fees and Others		1,863,488	1,475,021
Depreciation		13,283,436	13,296,495
Other Expenses		27,072,649	32,081,411
		114,893,879	122,120,893
Less: Expenses for INM		(12,533,233)	(9,472,142)
		102,360,646	112,648,751
25.A CONSOLIDATED ADMINISTRATIVE EXPENSES :			
Salary, Wages & Allowances		70,574,917	67,676,922
Repairs & Maintenance		7,812,093	9,864,673
Travelling & Conveyance		4,378,621	2,627,748
AGM, Fees and Others		1,863,488	1,977,954
Research & Development		1,417,174	221,263
Depreciation		17,597,700	17,414,296
Other Expenses		31,730,193	34,332,163
		135,374,187	134,115,019

- i) Salary, wages & allowance increased due to increase in manpower, gratuity payment.
- ii) Repairs & Maintenance expense decreased due to decrease in maintenance of fixed assets to meet business needs.
- iii) Travelling & conveyance increased during the period due to increase travel.
- iv) Research & development expense increased during this period due to meet business needs.
- iv) Depreciation expense during the reporting period increased due to addition of fixed assets .

		Amount in Taka	
		For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
26. SELLING & DISTRIBUTION EXPENSES :			
Salary, Wages & Allowances		1,034,334,780	868,657,372
Travelling & Conveyance		3,700,164	4,360,057
Market Survey & Research and Product development		4,473,744	3,243,031
Field personnel expenses		280,953,259	180,972,115
Sample, Literature & Promotional Expenses		191,880,137	113,936,626
Delivery Expenses		256,861,570	152,426,107
Depreciation		19,559,692	21,031,487
Other Expenses		168,439,518	215,456,981
		1,960,202,865	1,560,083,776
Less: Expenses for INM		(32,354,014)	(20,805,105)
		1,927,848,851	1,539,278,671
26.A CONSOLIDATED SELLING & DISTRIBUTION EXPENSES :			
Salary, Wages & Allowances		1,221,726,440	1,024,615,340
Travelling & Conveyance		6,395,744	5,938,539
Market Survey & Research and Product development		4,473,744	3,243,031
Field personnel expenses		326,019,127	219,319,478
Sample, Literature & Promotional Expenses		213,652,536	147,351,034
Delivery Expenses		256,861,570	152,426,106
Depreciation		19,788,912	21,243,927
Other Expenses		179,146,257	222,654,144
		2,228,064,330	1,796,791,600
i) Travelling & conveyance increased during the period due to increase travel.			
ii) Field personal and delivery expense during the reporting period increased due to increase in fuel and gas cost and vehicles rent cost.			
iii) Depreciation expense during the reporting period decreased due to disposal of fixed assets .			
27. WORKERS' P.P FUND & WELFARE FUND :		30,061,938	23,993,196
27.A CONSOLIDATED WORKERS' P.P FUND & WELFARE FUND :			
The IBN SINA Pharmaceutical Industry PLC		30,061,938	23,993,196
The IBN SINA Natural Medicine Ltd.		2,067,943	1,297,611
		32,129,881	25,290,807
28. INCOME TAX EXPENSES:			
Current Tax		129,701,593	106,324,177
Deferred Tax income/(expense)		3,308,099	6,612,236
		133,009,692	112,936,413
Reconciliation of Effective Tax Rate			
Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	601,238,759	20.00%	120,247,752
	601,238,759	20.00%	120,247,752
Non Deductible Expenses		1.57%	9,453,842
Deferred Tax (income)/expense		0.55%	3,308,099
		22.12%	133,009,692

		Amount in Taka	
		For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
28.A CONSOLIDATED INCOME TAX EXPENSES:			
Current Tax		141,903,654	110,330,579
Deferred Tax income/(expense)		3,415,147	6,597,297
		<u>145,318,801</u>	<u>116,927,876</u>
Reconciliation of Effective Tax Rate			
Types of income	Income	Effective Tax Rate	Tax
Capital Gain	-	20.00%	-
Business Income	622,549,918	20% to 27.50%	128,528,911
	<u>622,549,918</u>	<u>20.65%</u>	<u>128,528,911</u>
Non Deductible Expenses		1.52%	9,453,842
Deferred Tax (income)/expense		0.53%	3,308,099
		<u>22.70%</u>	<u>141,290,851</u>
29. CHANGE IN FAIR VALUE OF MARKETABLE SECURITIES :			
Closing value of marketable securities		(23,226,568)	(12,623,929)
Opening value of marketable securities		(17,271,479)	(9,567,467)
		<u>(5,955,089)</u>	<u>(3,056,462)</u>
30. EARNINGS PER SHARE (EPS) :			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		468,229,066	366,927,499
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
EARNINGS PER SHARE (EPS)		<u>14.99</u>	<u>11.74</u>
30.A CONSOLIDATED EARNINGS PER SHARE (EPS) :			
Basic earnings per share has been calculated as follows :			
Earnings attributable to the Ordinary Shareholders (Net profit after tax)		477,231,117	295,867,185
Divided by number of Ordinary Shares outstanding during the year/period		31,243,627	31,243,627
CONSOLIDATED EARNINGS PER SHARE (EPS) :		<u>15.27</u>	<u>9.47</u>
31. NET ASSETS VALUE PER SHARE (NAV)			
Equity attributable to the owners of the company		4,195,293,329	3,932,383,056
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
Net Assets Value Per Share (NAV)		<u>134.28</u>	<u>125.86</u>
Net Assets Value Per Share (NAV) increased during the period due to increase in sales, maintaining stable expenses growth and increase in retained earning.			
31.A CONSOLIDATED NET ASSETS VALUE PER SHARE (NAV):			
Net Assets Value		4,199,497,399	3,926,901,664
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
Consolidated Net Assets Value Per Share (NAV):		<u>134.41</u>	<u>125.69</u>

		Amount in Taka	
		For the half-year (1 July 2025 to 31 December 2025)	For the half-year (1 July 2024 to 31 December 2024)
32. NET OPERATING CASH FLOW PER SHARE (NOCFPS):			
Net cash provided by operating activities		749,845,390	507,212,831
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		24.00	16.23
32.A CONSOLIDATED NET OPERATING CASH FLOWS PER SHARE (NOCFPS):			
Net cash provided by operating activities		767,873,543	538,814,680
Divided by weighed average number of Ordinary Shares outstanding during the period		31,243,627	31,243,627
		24.58	17.25
33. RECONCILIATION OF NET PROFIT WITH CASH FLOWS FROM OPERATING ACTIVITIES:			
Profit Before Tax (PBT)		601,238,759	479,863,911
Adjustment			
Depreciation		100,150,632	98,184,730
Deferred Tax		3,903,608	6,917,882
Unrealized foreign exchange loss		(3,423,332)	46,902
Share of associate profit/Loss		1,270,038	1,247,355
Gain on sale of Motor Vehicles		-	-
Dividend received		-	1,869,684
Interest Income		(1,656,524)	-
Change In operating assets			
Increase in inventory		(63,118,694)	(27,221,822)
Increase in accounts receivables		(28,144,840)	(5,820,181)
Decrease in advances, deposits and prepayments		1,582,663	6,942,226
Increase/(decrease) in trade and other payable		262,360,562	58,231,441
Increase/(decrease) in retirement benefit obligation		638,540	511,076
Finance charge		(50,506,436)	(36,620,120)
Tax paid during the period		(74,449,586)	(76,940,255)
		749,845,390	507,212,831
34. Finance Charge:			
Finance charge for long term finance		50,506,436	36,620,120
Finance charge for lease		946,143	2,133,503
		51,452,579	38,753,623
34.A Consolidated Finance Charge:			
Finance charge for long term finance		50,506,436	36,620,120
Finance charge for lease		946,143	2,133,503
		51,452,579	38,753,623



35. RELATED PARTY DISCLOSURE:

Name of party	Relations hip	Nature of transaction	Transaction		Dec' 2025	June 2025
			Dr.	Cr.	Receivable/(Payable)	
The IBN SINA API Industry Ltd.	Subsidiary (99.99%)	Acquisition of share Capital		40,000,000	709,999,800	669,999,800
The IBN SINA Natural Medicine Ltd.	Subsidiary (99.99%)	Acquisition of share Capital			238,169,670	238,169,670
		Administrative Expenses	12,533,233			
		Distribution Expense	32,354,014		-	
The IBN SINA Polymer Industry Ltd.	Subsidiary (65%)	Acquisition of share Capital	-	65,000,000	195,000,000	130,000,000


35.01. NON-CONTROLLING INTEREST

The IBN SINA API Industry Ltd.


The IBN SINA Natural Medicine Ltd.

The IBN SINA Polymer Industry Ltd.


Profit Amount	NCI (%)	Net Amount
(18,554,363)	0.000050	(9)
29,210,175	0.001260	368
(1,953,631)	35.000000	(683,771)
8,702,181		(683,412)


Chief Financial Officer


Company Secretary


Director

Dated, Dhaka .
26 January 2026


Managing Director


Chairman